EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients

Ji Su Lee, Jimin Woo, Tae Min Kim, Namkyu Kim, Bhumsuk Keam, Seong Jin Jo

Acta Dermato-Venereologica · 28.08.2024 · 104 · adv40555

DOI: 10.2340/actadv.v104.40555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 28.08.2024. Verfasst von Ji Su Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Seoul National University Hospital, Seoul, Korea; Laboratory of Cutaneous Aging and Hair Research, Clinical Research Insti…. Hauptthemen laut MEDLINE: Lung Neoplasms, Protein Kinase Inhibitors, ErbB Receptors, Drug Eruptions. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation. This retrospective study aimed to profile skin toxicities and their impact on treatment adjustments. A total of 288 non-small cell lung cancer patients treated with first-, second-, or third-generation epidermal growth factor receptor tyrosine kinase inhibitors were included. Skin toxicities, including papulopustular rash, xerosis, paronychia, and pruritus, were assessed based on medical records, and their severity was evaluated based on the required dermatological intervention. Papulopustular rash was the most common toxicity (74.3%), followed by pruritus (61.1%), xerosis (52.4%), and paronychia (39.6%). Papulopustular rash was more common in males and more severe in younger patients. Papulopustular rash was more prevalent in patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors, while paronychia was notably frequent for the second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors frequently caused multiple skin toxicities. Importantly, skin toxicities led to epidermal growth factor receptor tyrosine kinase inhibitor treatment adjustments in 26.7% of cases, with second-generation epidermal growth factor receptor tyrosine kinase inhibitors demonstrating higher adjustment rates. Papulopustular rash and paronychia were the main causes of treatment adjustments, with even mild paronychia being linked to treatment adjustments. Effective management of skin toxicities is essential for optimizing treatment outcomes in patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsProtein Kinase InhibitorsErbB ReceptorsDrug EruptionsCarcinoma, Non-Small-Cell LungHumansMaleFemaleRetrospective StudiesAgedMiddle AgedAntineoplastic AgentsAged, 80 and overAdultTreatment OutcomeSeverity of Illness IndexRisk FactorsParonychiaTyrosine Kinase Inhibitors

Substanzen

Protein Kinase InhibitorsErbB ReceptorsAntineoplastic AgentsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, Seoul National University Hospital, Seoul, Korea; Laboratory of Cutaneous Aging and Hair Research, Clinical Research Institute, Seoul National University Hospital, Seoul, Korea; Institute of H…
  • Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Dermatology, Seoul National University Hospital, Seoul, Korea; Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University, Seoul, Republic of Korea.

Zitieren

APA

Lee, J. S., Woo, J., Kim, T. M., Kim, N., Keam, B., & Jo, S. J. (2024). Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients. Acta Dermato-Venereologica, 104, adv40555. https://doi.org/10.2340/actadv.v104.40555

Vancouver

Lee JS, Woo J, Kim TM, Kim N, Keam B, Jo SJ. Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients. Acta Dermato-Venereologica. 2024;104:adv40555. doi:10.2340/actadv.v104.40555

BibTeX
@article{Lee2024,
  author = {Lee, Ji Su and Woo, Jimin and Kim, Tae Min and Kim, Namkyu and Keam, Bhumsuk and Jo, Seong Jin},
  title = {Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients},
  journal = {Acta Dermato-Venereologica},
  year = {2024},
  volume = {104},
  pages = {adv40555},
  doi = {10.2340/actadv.v104.40555}
}
Kostenlos starten →